- Stocks
- Healthcare
- NASDAQ: CLSD

Price (delayed)

$2.38

Market cap

$136.67M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$121.1M

CLSD's debt has dropped by 69% year-on-year and by 3.4% since the previous quarter

The EPS has surged by 52% year-on-year but it has declined by 26% since the previous quarter

The company's net income rose by 41% YoY but it fell by 28% QoQ

The revenue has contracted by 20% from the previous quarter

The company's gross profit fell by 20% QoQ

What are the main financial stats of CLSD

Market
Valuations
Earnings

Shares outstanding

57.42M

Market cap

$136.67M

Enterprise value

$121.1M

Price to earnings (P/E)

N/A

Price to book (P/B)

13.13

Price to sales (P/S)

14.02

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

15.34

Revenue

$7.89M

EBIT

-$18.21M

EBITDA

-$18.03M

Free cash flow

-$13.18M

Per share
Balance sheet
Liquidity

EPS

-$0.39

Free cash flow per share

-$0.28

Book value per share

$0.18

Revenue per share

$0.17

TBVPS

$0.42

Total assets

$19.32M

Total liabilities

$10.56M

Debt

$1.98M

Equity

$8.76M

Working capital

$8.18M

Debt to equity

0.23

Current ratio

1.82

Quick ratio

1.76

Net debt/EBITDA

0.86

Margins
Efficiency
Dividend

EBITDA margin

-228.4%

Gross margin

100%

Net margin

-230.7%

Operating margin

-227.2%

Return on assets

-91.6%

Return on equity

-210.4%

Return on invested capital

N/A

Return on capital employed

-194.2%

Return on sales

-230.7%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Clearside Biomedical stock price performed over time

Intraday

2.59%

1 week

-12.5%

1 month

-10.86%

1 year

11.74%

YTD

-13.14%

QTD

-3.64%

How have Clearside Biomedical's revenue and profit performed over time

Revenue

$7.89M

Gross profit

$7.89M

Operating income

-$17.94M

Net income

-$18.21M

Gross margin

100%

Net margin

-230.7%

The operating margin has soared by 84% YoY but it has plunged by 63% from the previous quarter

CLSD's net margin has surged by 84% year-on-year but it has dropped by 60% since the previous quarter

The company's net income rose by 41% YoY but it fell by 28% QoQ

The operating income has grown by 41% YoY but it has contracted by 31% from the previous quarter

What is Clearside Biomedical's growth rate over time

What is Clearside Biomedical stock price valuation

P/E

N/A

P/B

13.13

P/S

14.02

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

15.34

The EPS has surged by 52% year-on-year but it has declined by 26% since the previous quarter

The price to book (P/B) is 117% higher than the 5-year quarterly average of 5.9 and 20% higher than the last 4 quarters average of 10.7

CLSD's equity is down by 21% year-on-year but it is up by 8% since the previous quarter

The P/S is 99% below the 5-year quarterly average of 1347.1 but 12% above the last 4 quarters average of 12.2

The revenue has contracted by 20% from the previous quarter

How efficient is Clearside Biomedical business performance

The return on sales has surged by 84% year-on-year but it has dropped by 60% since the previous quarter

The company's return on assets fell by 40% QoQ but it rose by 11% YoY

The return on equity has declined by 37% since the previous quarter but it has grown by 15% year-on-year

What is CLSD's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CLSD.

How did Clearside Biomedical financials performed over time

The company's total assets is 83% higher than its total liabilities

The total liabilities is down by 32% YoY but it is up by 14% from the previous quarter

The company's total assets fell by 28% YoY but it rose by 11% QoQ

CLSD's debt is 77% smaller than its equity

CLSD's debt has dropped by 69% year-on-year and by 3.4% since the previous quarter

The debt to equity has plunged by 60% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.